Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the prevention of COPD exacerbations) trial.
A Koneti RaoFabiola Del Carpio-CanoSumalaxmi JanapatiHuaqing ZhaoHelen VoelkerXiaoning LuGerard Crinernull nullPublished in: Journal of thrombosis and haemostasis : JTH (2021)
In contrast to previous studies on statins, in COPD patients without diabetes, cardiovascular disease, or requiring a statin treatment, simvastatin (40 mg per day) did not decrease TF or factors VIIa and VIII, fibrinogen, TAT, or D-dimer. The decreases in TFPI and factor VII reflect the decrease in serum lipids.
Keyphrases
- cardiovascular disease
- chronic obstructive pulmonary disease
- type diabetes
- ejection fraction
- cystic fibrosis
- coronary artery disease
- magnetic resonance
- study protocol
- cardiovascular events
- cardiovascular risk factors
- phase iii
- phase ii
- metabolic syndrome
- computed tomography
- fatty acid
- patient reported outcomes
- smoking cessation
- chronic kidney disease
- air pollution
- peritoneal dialysis
- double blind